Edition:
United States

PAVmed Inc (PAVM.OQ)

PAVM.OQ on NASDAQ Stock Exchange Capital Market

2.91USD
8 Dec 2017
Change (% chg)

$-0.02 (-0.68%)
Prev Close
$2.93
Open
$2.99
Day's High
$3.07
Day's Low
$2.82
Volume
7,786
Avg. Vol
4,308
52-wk High
$9.25
52-wk Low
$2.59

Latest Key Developments (Source: Significant Developments)

Pavmed Files 510(K) Submission With Fda For Carpx Device To Treat Carpal Tunnel Syndrome
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Pavmed Inc ::PAVMED FILES 510(K) SUBMISSION WITH FDA FOR CARPX™ DEVICE TO TREAT CARPAL TUNNEL SYNDROME.PAVMED INC - ‍TARGETING CLEARANCE FOR 510(K) PREMARKET NOTIFICATION SUBMISSION FOR CARPX DEVICE IN FIRST HALF OF 2018​.  Full Article

Pavmed reports Q3 adjusted non-GAAP loss per share $0.13
Wednesday, 15 Nov 2017 07:30am EST 

Nov 15 (Reuters) - Pavmed Inc :Pavmed reports third quarter 2017 financial results.Q3 GAAP loss per share $0.40.Q3 adjusted non-GAAP loss per share $0.13.  Full Article

Pavmed offers up to 2.7 mln shares
Wednesday, 8 Nov 2017 06:23am EST 

Nov 8 (Reuters) - Pavmed Inc ::Pavmed files for offering of up to 2.7 million shares of co that may be offered for resale by selling stockholders - SEC filing.  Full Article

Pavmed says has received a letter from FDA regarding its portio intraosseous infusion system​
Tuesday, 3 Oct 2017 05:41pm EDT 

Oct 3 (Reuters) - Pavmed Inc :Pavmed Inc - has received a letter from food and drug administration regarding its portio intraosseous infusion system​.Pavmed Inc - co has decided to follow fda s encouragement and pursue a de novo classification for portio under a broader indication, for up to 7 days​.Pavmed - ‍ after pursuing de novo classification for portio under a broader indication, co intends to immediately pursue pre-submission meeting with FDA​.Pavmed - ‍fda determined that portio is not substantially equivalent to proposed predicate.Pavmed says ‍FDA encouraged company to pursue classification under section 513(f)(2) of federal food, drug, and cosmetic act​ - SEC Filing.  Full Article

PAVmed files for mixed shelf of up to $75 million
Thursday, 21 Sep 2017 06:20am EDT 

Sept 21 (Reuters) - PAVmed Inc :PAVmed files for mixed shelf of up to $75 million - SEC filing.  Full Article

Pavmed CEO Lishan Aklog buys 9,100 shares of co's common stock
Friday, 25 Aug 2017 03:04pm EDT 

Aug 25 (Reuters) - Pavmed Inc :Pavmed Inc CEO ‍lishan Aklog reports purchase of 9,100 shares of co's common stock between Aug 23-24 - SEC filing ​.  Full Article

PAVmed Q1 adjusted loss 14 cents/shr
Monday, 22 May 2017 04:05pm EDT 

May 22 (Reuters) - PAVmed Inc :Pavmed reports first quarter 2017 financial results and provides business update.Q1 gaap loss per share $0.32.Q1 adjusted non-gaap loss per share $0.14.  Full Article

Pavmed files for non-timely 10-Q
Monday, 15 May 2017 05:56pm EDT 

May 15 (Reuters) - Pavmed Inc :Pavmed files for non-timely 10-Q.  Full Article

PAVmed files for resale of up to 3.93 mln common shares by the selling securityholders
Monday, 27 Mar 2017 04:48pm EDT 

PAVmed Inc - :Files for resale of up to 3.93 million shares of co's common stock by the selling securityholders - SEC filing.  Full Article

Pavmed reports Q2 results; provides update on carpX device
Tuesday, 16 Aug 2016 07:00am EDT 

PAVmed Inc : PAVmed Inc announces second quarter 2016 financial results and provides business update . Now initiated final design phase for commercial carpX device .To initiate formal verification, validation testing for commercial carpX device by end of year & submit 510(K) application to FDA in 2017.  Full Article

BRIEF-Pavmed Files 510(K) Submission With Fda For Carpx Device To Treat Carpal Tunnel Syndrome

* PAVMED FILES 510(K) SUBMISSION WITH FDA FOR CARPX™ DEVICE TO TREAT CARPAL TUNNEL SYNDROME